This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study (DEEP)

This study has been completed.
Information provided by (Responsible Party):
AtriCure, Inc. Identifier:
First received: November 22, 2010
Last updated: January 29, 2016
Last verified: January 2016
The purpose of this clinical investigation is to evaluate how safe a less invasive cardiac surgery is using the AtriCure Bipolar System combined with a catheter ablation procedure in treating AF, and how effective this combined procedure is using the AtriCure System in treating AF. The AtriCure Bipolar System will be used to perform the less invasive cardiac surgery and a standard electrophysiology catheter, currently available, will be used to perform the catheter ablation procedure. This surgical procedure is considered less invasive because it is done through tiny surgical punctures on the sides of the chest near the ribs instead of one large surgical incision of the breast bone to completely open the chest and access the heart, and it also avoids the need for the heart-lung bypass machine.

Condition Intervention Phase
Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation Device: Hybrid ablation procedure Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility Trial of a Hybrid Approach for Treatment of Patients With Persistent or Longstanding Persistent Atrial Fibrillation With Radiofrequency Ablation

Resource links provided by NLM:

Further study details as provided by AtriCure, Inc.:

Primary Outcome Measures:
  • composite of pre-specified safety endpoints occurring in the first 30 days post-index procedure or hospital discharge, whichever is longer. [ Time Frame: Within the first 30 days post-index procedure or hospital discharge ]
  • Absence of atrial fibrillation [ Time Frame: 12 month follow-up ]
    Absence of atrial fibrillation (AF) at twelve month follow-up based on an auto trigger event monitor, while off all Class I and III antiarrhythmic therapy.

Secondary Outcome Measures:
  • Overall Serious Device or Procedure Related Adverse Event Rate [ Time Frame: 12 month follow-up ]
  • Acute Procedure Success [ Time Frame: Upon completion of the index procedure ]
  • Absence of atrial fibrillation [ Time Frame: 12 month ]
    Absence of atrial fibrillation after the 3 month blanking period through twelve month follow-up based on auto trigger event monitor.

  • Incidence of Reintervention [ Time Frame: 12 months ]
  • Incidence of DC cardioversion [ Time Frame: 12 months ]
  • Improvement in AF [ Time Frame: 12 months ]
    Improvement in AF Symptom Checklist Frequency and Severity Scores.

  • Duration of procedure [ Time Frame: index procedure ]

Enrollment: 24
Study Start Date: November 2010
Study Completion Date: November 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AtriCure Bipolar System combined with a catheter ablation
procedure using the AtriCure Bipolar System plus a catheter ablation
Device: Hybrid ablation procedure
AtriCure Bipolar System plus a catheter ablation


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age > 18 years
  2. Patients with symptomatic (e.g. palpitations, shortness of breath, fatigue) persistent or longstanding persistent AF Persistent
  3. Patient is willing and able to provide written informed consent.
  4. Patient has a life expectancy of at least 2 years.
  5. Patient is willing and able to attend the scheduled follow-up visits.

Exclusion Criteria:

  1. Prior Cardiothoracic Surgery.
  2. Patient has NYHA Class IV heart failure.
  3. Evidence of underlying structural heart disease requiring surgical treatment.
  4. Ejection fraction < 30%
  5. Measured left atrial diameter > 6.0 cm
  6. Renal Failure
  7. Stroke within previous 6 months.
  8. Known carotid artery stenosis greater than 80%.
  9. Evidence of significant active infection or endocarditis.
  10. Pregnant woman or women desiring to become pregnant in the next 24 months.
  11. Presence of thrombus in the left atrium determined by echocardiography.
  12. History of blood dyscrasia.
  13. Contraindication to anticoagulation, based on Investigator's opinion.
  14. Mural thrombus or tumor.
  15. Moderate to Severe COPD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01246466

United States, California
Stanford University Medical Center
Stanford, California, United States, 94305
United States, Tennessee
Vanderbilt Heart Institute
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor Health
Plano, Texas, United States, 75093
United States, Virginia
Charlottesville, Virginia, United States, 22908
Sentara Norfolk
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
AtriCure, Inc.
  More Information

Responsible Party: AtriCure, Inc. Identifier: NCT01246466     History of Changes
Other Study ID Numbers: CP2009-1
Study First Received: November 22, 2010
Last Updated: January 29, 2016

Keywords provided by AtriCure, Inc.:
Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation, Ablation, catheter ablation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on September 21, 2017